Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: A 4-week, dose-finding, open-label study with lanthanum carbonate

Nephrology Dialysis Transplantation

Volumn 19, Issue 7, 2004, Pages 1902-1906

  Hutchison, Alastair J ^a   Speake, Mary ^a   Al Baaj, Fouad ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Chronic renal failure; Dialysis; Dose titration; Hyperphosphataemia; Lanthanum carbonate; Phosphate

Indexed keywords

CALCICHEW; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL DERIVATIVE; LANTHANUM CARBONATE; PHOSPHATE BINDING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TITRIMETRY; VOMITING;

FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MIDDLE AGED; PHOSPHATES; RENAL DIALYSIS; TIME FACTORS; TITRIMETRY;

EID: 3242703940     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh282     Document Type: Article

References (13)

1. Block GA, Hulbert-Shearon TE, Levin MD, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 606-617
2. Slatopolsky E, Weerts C, Lopez-Hilker S et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315: 157-161
3. Sherrard DJ. Aluminum - much ado about something. N Engl J Med 1991; 324: 558-559
4. Locatelli F, Cannata-Andia JB, Drüeke TB et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002; 17: 723-731
5. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
6. Hutchison AJ, Boulton HF, Gokal R. Low-calcium dialysis fluid and oral calcium carbonate in CAPD: a method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Nephrol Dial Transplant 1992; 7: 1219-1225
7. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int 2000; 57: 1776-1777
8. Locatelli F, D'Amico M, Pontoriero G. Lanthanum carbonate (Shire). IDrugs 2003; 6: 688-695
9. Hutchison AJ. Calcitriol, lanthanum carbonate and other new phosphate binders in the management of renal osteodystrophy. Perit Dial Int 1999; 19 [Suppl 2]: S408-S412
10. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42: 96-107
11. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; 85: S73-S78
12. Hutchison AJ, Adams JE, Freemont AJ, Mawer EB, Gokal R. Correlation of bone histology with parathyroid hormone, vitamin D3 and radiology at start of CAPD. Kidney Int 1993; 44: 1071-1077
13. Hutchison AJ, Whitehouse RW, Freemont AJ, Adams JE, Mawer EB, Gokal R. Histological, radiological, and biochemical features of the adynamic bone lesion in CAPD Patients. Am J Nephrol 1994; 14: 19-29